http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107007814-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 |
| filingDate | 2016-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107007814-B |
| titleOfInvention | Application of cetrorelix in preparation of medicine for treating AIDS |
| abstract | The invention provides an application of cetrorelix and pharmaceutically acceptable salts thereof in preparing a medicine for treating AIDSApplication in medicine for treating AIDS. Selecting human T lymphocyte cell line C8166 and HIV-1 experimental strain HIV-1 NL4‑3 Cetrorelix was tested for cytotoxicity and anti-HIV activity in vitro using MTT colorimetry, and anti-HIV activity was tested using both syncytia inhibition assay and HIV-1p24 antigen quantification. The results demonstrate that cetrorelix has little toxicity to cells, CC 50 >200 mu M; at a concentration equal to EC 50 (1.788. mu.M), cetrorelix was completely non-toxic to cell C8166. Therefore, cetrorelix can be used as an anti-HIV drug. |
| priorityDate | 2016-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.